Diagnostic strategies towards clinical implementation of liquid biopsy RAS/BRAF circulating tumor DNA analyses in patients with metastatic colorectal cancer.

[1]  G. Kazemier,et al.  Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG) , 2015, BMC Cancer.

[2]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[3]  I. Tsigelny,et al.  Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. , 2018, Cancer discovery.

[4]  W. V. van Harten,et al.  Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis , 2016, Ecancermedicalscience.

[5]  P. Lønning,et al.  Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection , 2016, PLoS genetics.

[6]  Ritika Kundra,et al.  Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. , 2018, Cancer cell.

[7]  M. Vincent,et al.  Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer , 2010, Current oncology.

[8]  P. Ulivi,et al.  Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine? , 2018, International journal of molecular sciences.

[9]  Sam Angiuoli,et al.  Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[10]  Yolande Lievens,et al.  Activity-based costing: a practical model for cost calculation in radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[11]  David R. Jones,et al.  A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. , 2018, Journal of the National Cancer Institute.

[12]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[13]  F. Rojo,et al.  Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer , 2018, British Journal of Cancer.

[14]  J. Meyerhardt,et al.  Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.

[15]  M. Fakih.  Metastatic colorectal cancer: current state and future directions. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[17]  Robyn L. Temple-Smolkin,et al.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. , 2017, The Journal of molecular diagnostics : JMD.

[18]  A. Bertotti,et al.  Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies , 2015, Clinical Cancer Research.

[19]  S. Kopetz,et al.  Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. , 2019 .

[20]  N. Normanno,et al.  RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[22]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[23]  V. Velculescu,et al.  Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA , 2013, Oncotarget.

[24]  Sabine Tejpar,et al.  KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. , 2011, The Lancet. Oncology.

[25]  R. Salazar,et al.  Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  C. Paweletz,et al.  False-Positive Plasma Genotyping Due to Clonal Hematopoiesis , 2018, Clinical Cancer Research.

[27]  Franck Molina,et al.  Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA , 2014, Nature Medicine.

[28]  C. Yeh,et al.  Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients , 2016, Oncotarget.

[29]  M. Peeters,et al.  Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. , 2015, European journal of cancer.

[30]  E. Van Cutsem,et al.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials , 2017, JAMA oncology.

[31]  R. Scharpf,et al.  The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.

[32]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[33]  G. Liguori,et al.  Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. , 2016, World journal of gastroenterology.

[34]  V. Papadimitrakopoulou,et al.  Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer , 2019, Clinical Cancer Research.

[35]  M. Kloor,et al.  The Association Between Mutations in BRAF and Colorectal Cancer–Specific Survival Depends on Microsatellite Status and Tumor Stage , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[37]  Mef Nilbert,et al.  The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis , 2014, Acta oncologica.